The Court of First Instance of the UPC, in decisions dated 4 and 31 July 2024, ordered the revocation within the relevant states of two European patents owned by Dexcom, Inc. relating to continuous glucose monitoring, EP3435866 and EP3797685. Dexcom, Inc. were the claimant in both cases, asserting the patents against Abbott Laboratories and several of its subsidiary companies (Abbott). In both cases, the court held that the patents lacked inventive step. Abbott were advised and represented by an international team led by Taylor Wessing which included Boult’s Daryl Penny. In particular, Daryl (one of Boult’s UPC Representatives) advised Abbott on the invalidity counterclaim. He attended the hearings before the Paris and Munich Local Divisions of the UPC as part of Abbott’s defence team. As well as having successful outcomes for Boult’s client, these decisions show how the UPC is analysing inventive step. We will report further soon. In the meantime, the full decisions can be foundhereandhere.
Relevant sectors
Food and beverage
Nutrition
Retail
Beverages
Artificial intelligence and machine learning
Consumer goods and retail
Anti-counterfeit devices
Moda
Health, fitness and sport
Beauty
Fashion
Luxury goods
Retail
Household goods
Trade marks
Mechanical products
Services
Telecommunications
Financial services
Cosmetics and perfumery
Consumer goods
Chemicals
Agrochemicals
Catalysts
Dispersions and colloids
Lubricants
Polymers and plastics
Materials
Advanced materials
Composite materials
Metallurgy and alloys
Nanotechnology
Industrial manufacturing and processing
Packaging
Polymers and plastics
Printing tech
Additive manufacturing
Coatings
Construction
Electronics and electrical devices
Restaurants and bars
Travel and leisure
Testing systems, control systems, signal processing
Computer and IT architecture and system design
Medical devices
Optics
Robotics
Scientific instruments
Semiconductor devices
Wearable tech and human interfaces
Communications and networks
Oceanography, marine
Cloud computing
Internet of things (IOT)
Wired and wireless networks
Energy and green technologies
Solar power
Wind turbines
Water, oil and gas, nuclear, fusion, fission
Clean air
Fuel cells and battery technology
Renewables and recycling
Biofuels
Automotive
Autonomous vehicles
Electric vehicles
Engines
Aerospace
Commercial aviation
Defence and security
Space and satellites
Unmanned aerial vehicles
Pharmaceuticals
Pharmaceuticalsceutical formulations
Diagnostics
Drug delivery
Generic market entry
Medicinal chemistry
Methods of production and synthesis
Personalised medicine/disease biomarkers
Pharmaceutical formulations
Polymorphs
Small molecule pharmaceuticals
Supplementary protection certificates (SPCs)
Biotechnology
Bioinformatics
Next generation sequencing
Women’s health products
Vaccinology (e.g. viral vectors; mRNA vaccines)
Therapeutic antibodies
Synthetic biology
Stem cell therapies
Recombinant protein production and purification
Personalised medicine/disease biomarkers
Nucleic acid synthesis
Supplementary protection certificates (SPCs)
Immuno-oncology (e.g. checkpoint inhibitors; modified T cells)
GM crops
Genomic and molecular tools and methods
Gene editing (e.g. CRISPR)
Drug delivery
Biosimilars
Antibody manufacture and formulation
Antibody engineering
Medical devices and diagnostics
Immuno-oncology
Artificial intelligence
Devices
Diagnostic instruments
Digital health
Drug delivery
In vitro diagnostics
Medtech
Computing and software
Digital assistants, virtual assistants and software agents
Multimedia, audio/video processing and animation
Metaverse, virtual reality (VR) and augmented reality (AR)
Data management and storage, databases and data compression
Data and software security, cryptography and digital rights management (DRM)
Software applications and systems, mobile applications, user interfaces
